Loading…
Anticancer activity of oxovanadium compounds
Cytotoxic and antitumor activities of the biligand vanadyl derivative of L-malic acid, (bis-(L-malato)oxovanadium(IV) (VO(mal) 2 ), the inorganic vanadium(IV) compound, vanadyl sulfate (VOSO 4 ), the oxovanadium monocomplex with L-malic acid (VO(mal)), and the vanadyl biscomplex with acetylacetonate...
Saved in:
| Published in: | Biochemistry (Moscow). Supplement. Series B, Biomedical chemistry Biomedical chemistry, 2012-04, Vol.6 (2), p.164-170 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c349t-33f7ec680aa60f6afa46df970fa5e53407adb14801e2faaf2a615f16ba96cf1f3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c349t-33f7ec680aa60f6afa46df970fa5e53407adb14801e2faaf2a615f16ba96cf1f3 |
| container_end_page | 170 |
| container_issue | 2 |
| container_start_page | 164 |
| container_title | Biochemistry (Moscow). Supplement. Series B, Biomedical chemistry |
| container_volume | 6 |
| creator | Abakumova, O. Yu Podobed, O. V. Belayeva, N. F. Tochilkin, A. I. |
| description | Cytotoxic and antitumor activities of the biligand vanadyl derivative of L-malic acid, (bis-(L-malato)oxovanadium(IV) (VO(mal)
2
), the inorganic vanadium(IV) compound, vanadyl sulfate (VOSO
4
), the oxovanadium monocomplex with L-malic acid (VO(mal)), and the vanadyl biscomplex with acetylacetonate (VO(acac)
2
) were investigated using several tumor cell lines: mouse fibrosarcoma (L929), rat pheochromocytoma (PC12), human liver carcinoma (HepG2), mouse embryonic fibroblasts (NIH/3T3), and also normal human skin fibroblasts. The results showed that VO(mal)
2
effectively inhibited growth of cancer cell cultures without any toxic effect on normal human skin fibroblasts. The cytotoxic anticancer effect of vanadium complexes depended on concentration of the compounds studied, incubation time, types of cell cultures, and nature of ligands surrounding the central group of the complex (VO
2+
). These studies provide evidence that VO(mal)
2
may be considered as a potential anticancer agent due to its low toxicity for non-tumor cells and significant anticancer activity. |
| doi_str_mv | 10.1134/S1990750812020023 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1496897293</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1496897293</sourcerecordid><originalsourceid>FETCH-LOGICAL-c349t-33f7ec680aa60f6afa46df970fa5e53407adb14801e2faaf2a615f16ba96cf1f3</originalsourceid><addsrcrecordid>eNp1kE1LxDAQhoMouK7-AG8FLx6sziRt2hyXxS9Y8KCey2yaSJdtsybt4v57s1REFE8zDM_zMryMnSNcI4rs5hmVgiKHEjlwAC4O2GR_Sosc5eH3DuUxOwlhBSBRqGzCrmZd32jqtPEJ6b7ZNv0ucTZxH25LHdXN0CbatRs3dHU4ZUeW1sGcfc0pe727fZk_pIun-8f5bJFqkak-FcIWRssSiCRYSZYyWVtVgKXc5CKDguolZiWg4ZbIcpKYW5RLUlJbtGLKLsfcjXfvgwl91TZBm_WaOuOGUGGmZKkKrkREL36hKzf4Ln5XIWApeIzmkcKR0t6F4I2tNr5pye8iVO37q_70Fx0-OiGy3ZvxP5P_kz4BfXBwxw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1018326152</pqid></control><display><type>article</type><title>Anticancer activity of oxovanadium compounds</title><source>Springer Nature</source><creator>Abakumova, O. Yu ; Podobed, O. V. ; Belayeva, N. F. ; Tochilkin, A. I.</creator><creatorcontrib>Abakumova, O. Yu ; Podobed, O. V. ; Belayeva, N. F. ; Tochilkin, A. I.</creatorcontrib><description>Cytotoxic and antitumor activities of the biligand vanadyl derivative of L-malic acid, (bis-(L-malato)oxovanadium(IV) (VO(mal)
2
), the inorganic vanadium(IV) compound, vanadyl sulfate (VOSO
4
), the oxovanadium monocomplex with L-malic acid (VO(mal)), and the vanadyl biscomplex with acetylacetonate (VO(acac)
2
) were investigated using several tumor cell lines: mouse fibrosarcoma (L929), rat pheochromocytoma (PC12), human liver carcinoma (HepG2), mouse embryonic fibroblasts (NIH/3T3), and also normal human skin fibroblasts. The results showed that VO(mal)
2
effectively inhibited growth of cancer cell cultures without any toxic effect on normal human skin fibroblasts. The cytotoxic anticancer effect of vanadium complexes depended on concentration of the compounds studied, incubation time, types of cell cultures, and nature of ligands surrounding the central group of the complex (VO
2+
). These studies provide evidence that VO(mal)
2
may be considered as a potential anticancer agent due to its low toxicity for non-tumor cells and significant anticancer activity.</description><identifier>ISSN: 1990-7508</identifier><identifier>EISSN: 1990-7516</identifier><identifier>DOI: 10.1134/S1990750812020023</identifier><language>eng</language><publisher>Dordrecht: SP MAIK Nauka/Interperiodica</publisher><subject>Apoptosis ; Biochemistry ; Bioorganic Chemistry ; Cancer ; Cell culture ; Chemistry ; Chemistry and Materials Science ; Medicinal Chemistry ; Trace elements</subject><ispartof>Biochemistry (Moscow). Supplement. Series B, Biomedical chemistry, 2012-04, Vol.6 (2), p.164-170</ispartof><rights>Pleiades Publishing, Ltd. 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c349t-33f7ec680aa60f6afa46df970fa5e53407adb14801e2faaf2a615f16ba96cf1f3</citedby><cites>FETCH-LOGICAL-c349t-33f7ec680aa60f6afa46df970fa5e53407adb14801e2faaf2a615f16ba96cf1f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Abakumova, O. Yu</creatorcontrib><creatorcontrib>Podobed, O. V.</creatorcontrib><creatorcontrib>Belayeva, N. F.</creatorcontrib><creatorcontrib>Tochilkin, A. I.</creatorcontrib><title>Anticancer activity of oxovanadium compounds</title><title>Biochemistry (Moscow). Supplement. Series B, Biomedical chemistry</title><addtitle>Biochem. Moscow Suppl. Ser. B</addtitle><description>Cytotoxic and antitumor activities of the biligand vanadyl derivative of L-malic acid, (bis-(L-malato)oxovanadium(IV) (VO(mal)
2
), the inorganic vanadium(IV) compound, vanadyl sulfate (VOSO
4
), the oxovanadium monocomplex with L-malic acid (VO(mal)), and the vanadyl biscomplex with acetylacetonate (VO(acac)
2
) were investigated using several tumor cell lines: mouse fibrosarcoma (L929), rat pheochromocytoma (PC12), human liver carcinoma (HepG2), mouse embryonic fibroblasts (NIH/3T3), and also normal human skin fibroblasts. The results showed that VO(mal)
2
effectively inhibited growth of cancer cell cultures without any toxic effect on normal human skin fibroblasts. The cytotoxic anticancer effect of vanadium complexes depended on concentration of the compounds studied, incubation time, types of cell cultures, and nature of ligands surrounding the central group of the complex (VO
2+
). These studies provide evidence that VO(mal)
2
may be considered as a potential anticancer agent due to its low toxicity for non-tumor cells and significant anticancer activity.</description><subject>Apoptosis</subject><subject>Biochemistry</subject><subject>Bioorganic Chemistry</subject><subject>Cancer</subject><subject>Cell culture</subject><subject>Chemistry</subject><subject>Chemistry and Materials Science</subject><subject>Medicinal Chemistry</subject><subject>Trace elements</subject><issn>1990-7508</issn><issn>1990-7516</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNp1kE1LxDAQhoMouK7-AG8FLx6sziRt2hyXxS9Y8KCey2yaSJdtsybt4v57s1REFE8zDM_zMryMnSNcI4rs5hmVgiKHEjlwAC4O2GR_Sosc5eH3DuUxOwlhBSBRqGzCrmZd32jqtPEJ6b7ZNv0ucTZxH25LHdXN0CbatRs3dHU4ZUeW1sGcfc0pe727fZk_pIun-8f5bJFqkak-FcIWRssSiCRYSZYyWVtVgKXc5CKDguolZiWg4ZbIcpKYW5RLUlJbtGLKLsfcjXfvgwl91TZBm_WaOuOGUGGmZKkKrkREL36hKzf4Ln5XIWApeIzmkcKR0t6F4I2tNr5pye8iVO37q_70Fx0-OiGy3ZvxP5P_kz4BfXBwxw</recordid><startdate>20120401</startdate><enddate>20120401</enddate><creator>Abakumova, O. Yu</creator><creator>Podobed, O. V.</creator><creator>Belayeva, N. F.</creator><creator>Tochilkin, A. I.</creator><general>SP MAIK Nauka/Interperiodica</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88I</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>20120401</creationdate><title>Anticancer activity of oxovanadium compounds</title><author>Abakumova, O. Yu ; Podobed, O. V. ; Belayeva, N. F. ; Tochilkin, A. I.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c349t-33f7ec680aa60f6afa46df970fa5e53407adb14801e2faaf2a615f16ba96cf1f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Apoptosis</topic><topic>Biochemistry</topic><topic>Bioorganic Chemistry</topic><topic>Cancer</topic><topic>Cell culture</topic><topic>Chemistry</topic><topic>Chemistry and Materials Science</topic><topic>Medicinal Chemistry</topic><topic>Trace elements</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abakumova, O. Yu</creatorcontrib><creatorcontrib>Podobed, O. V.</creatorcontrib><creatorcontrib>Belayeva, N. F.</creatorcontrib><creatorcontrib>Tochilkin, A. I.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Science Journals</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Biochemistry (Moscow). Supplement. Series B, Biomedical chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abakumova, O. Yu</au><au>Podobed, O. V.</au><au>Belayeva, N. F.</au><au>Tochilkin, A. I.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anticancer activity of oxovanadium compounds</atitle><jtitle>Biochemistry (Moscow). Supplement. Series B, Biomedical chemistry</jtitle><stitle>Biochem. Moscow Suppl. Ser. B</stitle><date>2012-04-01</date><risdate>2012</risdate><volume>6</volume><issue>2</issue><spage>164</spage><epage>170</epage><pages>164-170</pages><issn>1990-7508</issn><eissn>1990-7516</eissn><abstract>Cytotoxic and antitumor activities of the biligand vanadyl derivative of L-malic acid, (bis-(L-malato)oxovanadium(IV) (VO(mal)
2
), the inorganic vanadium(IV) compound, vanadyl sulfate (VOSO
4
), the oxovanadium monocomplex with L-malic acid (VO(mal)), and the vanadyl biscomplex with acetylacetonate (VO(acac)
2
) were investigated using several tumor cell lines: mouse fibrosarcoma (L929), rat pheochromocytoma (PC12), human liver carcinoma (HepG2), mouse embryonic fibroblasts (NIH/3T3), and also normal human skin fibroblasts. The results showed that VO(mal)
2
effectively inhibited growth of cancer cell cultures without any toxic effect on normal human skin fibroblasts. The cytotoxic anticancer effect of vanadium complexes depended on concentration of the compounds studied, incubation time, types of cell cultures, and nature of ligands surrounding the central group of the complex (VO
2+
). These studies provide evidence that VO(mal)
2
may be considered as a potential anticancer agent due to its low toxicity for non-tumor cells and significant anticancer activity.</abstract><cop>Dordrecht</cop><pub>SP MAIK Nauka/Interperiodica</pub><doi>10.1134/S1990750812020023</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1990-7508 |
| ispartof | Biochemistry (Moscow). Supplement. Series B, Biomedical chemistry, 2012-04, Vol.6 (2), p.164-170 |
| issn | 1990-7508 1990-7516 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1496897293 |
| source | Springer Nature |
| subjects | Apoptosis Biochemistry Bioorganic Chemistry Cancer Cell culture Chemistry Chemistry and Materials Science Medicinal Chemistry Trace elements |
| title | Anticancer activity of oxovanadium compounds |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T20%3A57%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anticancer%20activity%20of%20oxovanadium%20compounds&rft.jtitle=Biochemistry%20(Moscow).%20Supplement.%20Series%20B,%20Biomedical%20chemistry&rft.au=Abakumova,%20O.%20Yu&rft.date=2012-04-01&rft.volume=6&rft.issue=2&rft.spage=164&rft.epage=170&rft.pages=164-170&rft.issn=1990-7508&rft.eissn=1990-7516&rft_id=info:doi/10.1134/S1990750812020023&rft_dat=%3Cproquest_cross%3E1496897293%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c349t-33f7ec680aa60f6afa46df970fa5e53407adb14801e2faaf2a615f16ba96cf1f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1018326152&rft_id=info:pmid/&rfr_iscdi=true |